Colinz Laboratories Ltd Valuation
COLINZ · Healthcare · Current price ₹82
Is Colinz Laboratories Ltd undervalued?
DocStoX estimates the fair value of Colinz Laboratories Ltd at ₹52 per share, versus the current market price of ₹82. That puts the stock about -36.8% above our fair-value estimate, which we read as "Avoid". Our confidence in this estimate is medium.
How this fair value is calculated
This estimate blends 3 independent methods: Residual income (₹64), Relative P/E (₹33), Graham floor (₹42). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹33 (bear) to ₹52 (base) to ₹64 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
Valuation multiples
Colinz Laboratories Ltd trades at a P/E of 41.4x and a P/B of 1.1x, with a dividend yield of 0.0%. Multiples are most useful compared against the company's own history and its sector peers — see the peer comparison for context.
Understand the ratios
More on Colinz Laboratories Ltd
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.